Panelists

Barry Stein
President & CEO
Colorectal Cancer Canada

Alexandra Chambers
Director – pCODR
CADTH

Sujitha Ratnasingham
Director of Strategic Partnerships
ICES

Carole Chambers
Director of Pharmacy
Alberta Health Services

Virginie Giroux
Director, HEOR and Real World Evidence
Merck Canada
Stakeholder Engagement in Real World Evidence in Oncology
Why RWE in oncology?

1. Burden of cancer is growing
2. R&D pipeline for cancer treatments is changing and quickly evolving
3. Pressure on and from health systems to approve and adopt new cancer treatments quickly to address the burden
1. Burden of cancer is growing

- 200,000 new cases of cancer every year\(^1\)
- Increase in new cancer cases over next 12 years\(^2\)
- 1 in 2 Canadians will be diagnosed with cancer\(^1\)
- Nearly 81,000 deaths from cancer each year\(^1\)
- 1 in 4 is expected to die of cancer\(^1\)

\]
\]
\[\text{3. Claire de Oliveira, « The economic burden of cancer care in Canada: a population-based cost study », CMAJ: } \text{http://cmajopen.ca/content/6/1/E1.full}
\]
2. R&D pipeline for cancer treatments is changing and quickly evolving

Example of immuno-oncology pipeline

Specific challenges for reimbursing new cancer therapies:
• Highly targeted
• Smaller populations
• Shifting endpoints
• Higher uncertainty

Source: Kantar Health, July 2016
3. Pressure on and from health systems to approve and adopt cancer treatments quickly to address the burden

Start line for approval of new cancer therapies is moving up

**Regulators:**
Accelerating access to medicines that have the potential to address a high unmet need

**Payers:**
Having to make decisions based on more limited evidence
Today’s panel...

How can stakeholders best collaborate for patent-centric RWE in a reimbursement context?
We will need to unpack several questions...

- **What** is RWE or **where** do we get RWE (biomarkers, PROMs, patient registries, patient support programs, surveys, innovative CT designs, etc.)?
- **How** is RWE used and how could it be used to address gaps/opportunities?
- **What role** can stakeholders play in addressing the barriers and opportunities, remembering that patients have the most at stake in this? Pressure is building on all stakeholders to get this right.
Stakeholder Engagement in RWE Oncology

ALEX CHAMBERS
DIRECTOR, PCODR
Overview of Drug Review in Canada

- Health Canada
- CADTH (CDR and pCODR)
- INESSS (Quebec)
- Pan Canadian Pharmaceutical Alliance (pCPA)
- F/P/T Ministries of Health and Provincial Cancer Agencies
- Regulator (Effect & safety)
- HTA (Assess value)
- Price negotiator
- Decision maker/funder
How does pCODR use RWE?

1. Real world data/evidence has been used to supplement clinical trial data in pCODR reviews
2. Request for advice
Current post-pERC recommendation pathways

Positive/Conditional Recommendation:
- Under negotiation
- Reimbursed

Negative Recommendation:
- No negotiation
- New evidence

Implementation issue(s)

Request for Advice

CADTH Evidence Driven.
Example: RFA for Axitinib for Metastatic Renal Cell Carcinoma (mRCC)

• In 2013, pERC recommended the second-line use of axitinib in patients with mRCC who were unable to tolerate everolimus or had a contraindication to everolimus.
  • Uncertainty in the effectiveness of everolimus vs axitinib

• In 2017, Request by the Provincial Advisory Group (PAG):
  • Is there evidence to fund axitinib as an alternative to everolimus for the second-line treatment of metastatic clear cell renal carcinoma?
Example: RFA for Axitinib for mRCC

- pERC RFA Recommendation: pERC recommends reimbursement of axitinib as a second-line treatment for patients with mRCC.
  - Multiple sources of retrospective evidence demonstrated that there may not be a difference in clinical benefit between axitinib and everolimus.
  - No RCT comparing everolimus to axitinib, and unlikely that there will ever be a RCT.
  - Studies have limitations, but consistency in results.
Example: RFA for Axitinib for mRCC

- Stakeholder input: Kidney Cancer Canada (KCC)
  - KCC provided data from its Canadian Kidney Cancer Information System
    - A database of Canadian patients with kidney cancer that tracks kidney cancer treatment practice in Canada.
  - pERC remarked that “KCC’s input was valuable in noting the Canadian experience for metastatic RCC”.
RWE in ‘Next Steps’ of pERC Recommendations

- 51% Recommendations without RWE request
- 24% Recommendations with potential RWE request
- 25% Recommendations with RWE Request
Reasons for pERC Recommendations with RWE Requests

0 2 4 6 8 10 12 14

To inform magnitude of clinical benefit
To inform duration of treatment
To inform sequencing of available therapies
To inform QoL
To inform safety
To define the population or disease progression

CADTH Evidence Driven.
Why should we use RWE to help inform decisions by patients, clinicians, and payers?

- **ASCO Abstract 2018**: A comparison of clinical trial (CT) overall survival (OS) and toxicity data with population-based, real world (RW) OS data. *Phillips et al, 2018 ASCO (CCO study)*

- **Results**: 32 indications from 21 drugs (9 chemotherapy, 10 targeted therapies, 2 immunotherapy) involving 8,344 CT pts and 29,424 RW pts were included.

- **Conclusions**: In most cases, substantially worse OS and greater toxicity were observed in the RW compared to CTs.
How could pCODR use RWE?

• If data are collected, pCODR could conduct more RFAs to address questions of the jurisdictions.

• RWE could potentially be used to inform reassessments of drugs that are already funded to ensure that they are delivering value to the health system.
THANK YOU!
Stakeholder Engagement in RWE Oncology

Carole Chambers
CAPT Panel member
October 22, 2018
“Hand clapping for science is now inextricably linked to hand wringing over affordability.

RWE Considerations
“not one size fits all”

- Survival /outcomes – 7
- Adherence impacts -2
- Drug Interactions – 2
- Gender impacts - 1
- Other disease impacts – 1
- Physician behaviours – 1
Survival outcomes


- **Overall survival of 17 months was consistent with survival increase of 14.8 months observed in clinical trial.**


- In our clinical setting erlotinib did not perform as well in terms of median overall survival as reported in the pivotal clinical trial (5.19 vs 6.7 months)


- Alberta patients achieved overall and progression free survival similar to the clinical trial

• In our population docetaxel and prednisone did not perform as well in terms of median survival as in the pivotal clinical trial (17.22 vs 18.29 months)


• Performing less well in our population with respect to survival – monotherapy 10 vs 13 months, combination therapy 21 vs 25.1 months


• Results were comparable to that achieved in pivotal clinical trial.
Adherence


Our population was adherent 0.95 (0.83 to 1.07) compared to literature reports of 0.64 and 0.96


In our population majority of adjuvant patients remained on therapy for at least 2 years and were adherent.
Drug Interactions


- Erlotinib efficacy may be linked with gastric pH and OS could be adversely affected.


- Significant difference in progression free survival and overall survival between acid suppressed and no acid suppression groups.
Gender Impacts/Other Disease Impacts/Physician Behaviours

- Females experienced higher dose limiting toxicity than males when dosed according to BSA
- Introduction of HAART has dramatically reduced the amount spent on chemotherapy due to a decreased incidence of AIDS-related cancers even though the individual patient treatments have become more effective and expensive.
- As requested during listing the breast tumor group adopted capecitabine as the current primary choice of third line chemotherapy
How best can RWE be incorporated into current patient access pathway, in particular for medicines to treat cancer, and what is needed to make this happen?

- Consider phase 4 surveillance tools for initial two years of reimbursement to ensure no new harm signals and also gather expected outcomes

- Consider RWE collection during patient access programs under the consent given by the patient
What are the current key challenges and opportunities for RWE in the context of HTA reviews and reimbursement decisions?

- Challenges are that RWE is not really available for all HTA, not like clinical trials on which most HTA reviews are based.
- Opportunity to include in the patient section of HTA from compassionate access program patients.
Are public payors interested in using RWE to negotiate more outcomes based agreements?

• Yes and there have been some historically already

• Literature is emerging about the pros and cons of outcomes based agreements

• Public payors are interested in the patient outcomes as that is what we are all investing public dollars in
What are the opportunities for various health system stakeholders – in particular the pharmaceutical industry and patients – to collaborate with payers on RWE initiatives

- Patients providing consent for their health data to be incorporated in the RWE material

- Pharmaceutical companies to include this option in consent for the compassionate access programs and also for phase IV surveillance programs post launch
Can patient organizations and civil society act as enablers and facilitators for the generation of RWE?

- Absolutely yes.
- Enablers to expect this RWE to be collected and see how drugs perform in actual use.
- Facilitators by providing consent for your health data to inform the RWE.
Thank you
Stakeholder Engagement in RWE in Oncology

Sujitha Ratnasingham
Director, Strategic Partnerships
ICES

CAPT Conference
October 22, 2018
ICES Mission, Vision and Values

ICES is a not-for-profit research institute encompassing a community of research, data and clinical experts, and a secure and accessible array of Ontario's health-related data.

ICES MISSION
Our mission is research excellence resulting in trusted evidence that makes policy better, health care stronger and people healthier.

ICES VISION
Our vision is to be a world-leading institute where data and discovery improve health and health care.

ICES VALUES
Excellence    Integrity    Relevance    Collaboration
Respect
Data & Analytic Services (DAS)

- As part of the Strategy for Patient Oriented Research (SPOR) initiative, ICES has successfully launched ICES’ Data and Analytic Services (DAS) platform in 2014
- Enables external researchers to access ICES data previously unavailable to them, while maintaining ICES' privacy and security standards
- Adjudication of requests is done by a multidisciplinary team who assess feasibility and determine the resources needed to carry out their research

- **Services Available:**
  - **Access to Data (DAS Data)**
    - ICES Data and Analytic Virtual Environment (IDAVE)
    - Virtual workspace allows external researchers to access their project-specific data outside of ICES on a secure platform
  - **Access to Analytics (DAS Analytics)**
    - ICES staff perform analysis directed by external researchers

Data Available Through ICES DAS

Core datasets:
- These data are available to all researchers
- Examples of these data include the Discharge Abstract Database (DAD), National Ambulatory Care Reporting System (NACRS), Ontario Drug Benefit Claims (ODB), Ontario Health Insurance Plan Claims Database (OHIP), Registered Persons Database (RPDB), and the Ontario Cancer Registry (OCR)

Restricted datasets:
- These data are available for research which meets specific criteria
- Researchers may be required to seek additional approvals or collaborations, and in some cases the research objectives must align with predetermined guidelines
Why ICES Extended DAS to Private Sector Researchers

- Alignment with the Open Data initiative by Government of Ontario
- Potential to create knowledge that informs the ~30% of health care expenditures that are funded by the private sector
- Build on experience by other similar organizations in Canada and internationally who have provided similar access
DAS Private Sector Pilot

- ICES began 2 pilot projects in 2015 with private sector organizations under ICES' existing charitable organizational corporate structure

- Two pilots were successfully completed:
  - IMS Brogan, access to data for a study for their client AstraZeneca, “The disease burden of gout in Ontario – a real-world data retrospective study”
  - Janssen, analytic services, “The impact of adherence to biologics on healthcare resource utilization in rheumatoid arthritis”

- IMS Brogan and Janssen are actively pursuing publication of the findings of their studies
Stakeholder Engagement

• General public and scientists

• Focus groups and ideation sessions (ICES and non-ICES scientists)

• Areas of focus
  • Research using health administrative data
  • Appropriateness of expanding uses and users
  • Private sector researchers
Findings: General Public

- **Supportive of**
  - Research to support monitoring what is happening in health system and to aid planning
  - Consent to use data
  - ICES holding linked data: non-for-profit and independent
  - Privacy safeguards

- **Concerns**
  - Security of personal data: de-identification
  - Selling of private data for marketing/profiteering
Requirements for Private Sector Projects

• Aligns with ICES’ mission

  Research excellence resulting in trusted evidence that makes policy better, healthcare stronger and people healthier.

• Transparency principles
  • Final full-results reports, identities of private sector organizations, and analytic plans are publically available

• Financial viability

• Limited access to data (i.e. summary data only)
Data Available for Private Sector

- Hospital Discharge Abstract Database (DAD)
- National Ambulatory Care Reporting System (NACRS)
- Continuing Care Reporting System (CCRS)
- Ontario Drug Benefit Claims (ODB)
- Ontario Health Insurance Plan Claims Database (OHIP)
- Registered Persons Database (RPDB)
- Ontario Cancer Registry (OCR)
Additional DAS Private Sector Projects

• Additional projects have been completed by:

  - SHoppers Drug Mart
  - Sanofi Pasteur
  - Ims Brogan

• Ongoing projects:

  - Amgen
  - Roche
  - Pfizer

• Topics: Breast cancer epidemiology and treatment patterns, costing, burden of disease, etc.
Thank You

Questions:
Sujitha.ratnasingham@ices.on.ca
Patient Perspectives on Real World Evidence & Real World Data

Taking Action on Real World Evidence: From Analysis to Impact

Session 2: Stakeholder Engagement in RWE Oncology
October 22, 2018

Barry D. Stein
President CCO
An increasing focus on value-based healthcare has brought greater interest in RWE to assist with reimbursement decision making.

A number of countries, including Canada, are using various forms of RWE to assess healthcare interventions.

A consistent approach has not yet emerged and criteria defining when RWE might be required still needs to be established.
Patient Perspectives on Real World Evidence (RWE) and Real World Data (RWD)

RWE and RWD have the potential to provide patients, clinicians, and policymakers information that more traditional scientific studies cannot.

Patients often do not:
Have a full understanding of the complexities of generating RWE or be aware that there is a debate about the types of evidence used for the determination of safety and effectiveness of medical treatments.

Patients may assume:
Their providers have an ongoing feedback loop, and that their data is typically available for providers to use in choosing the right course of action or that RWD is already being incorporated into their treatment decisions.

Patients and Patient Groups can play an important role and their main concerns must be addressed:
“Will this work for me?” “Is this safe for me?”
Patients want …

✓ RWE generated from their experiences to be incorporated into value-driven decision making and policy discussions to ensure that the outcomes most important to them are considered.

✓ More control of their data and how it is used; they want their data used for research, but, generally do not want it used for only commercial purposes.

✓ Patients need a better understanding of RWE to both use and contribute.

Policymakers and advisory groups need to invest in educational efforts to inform and fully include the patient community in initiatives to establish standards for RWD and to use RWE more effectively.
THE NEED FOR STAKEHOLDERS TO AGREE

CENTRAL TO THE COLLECTION & INCREASED USE OF RWE IS A NEED TO AGREE ON A COMMON:

✓ DEFINITION OF RWE
✓ APPROPRIATE METHODOLOGY USED TO GATHER IT
✓ APPROPRIATE USE OF INFORMATION FOR HTA, POLICY, TREATMENTS
<table>
<thead>
<tr>
<th>Source</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>National Health Council Working Definition (USA) (Proposed)</td>
<td>Data and data-derived interpretation that is based on sources other than conventional, randomized controlled studies and offers insight to clinical, coverage, payment, and patient decisions.</td>
</tr>
<tr>
<td>FDA per 21st Century Cures Legislation. 21st Century Cures Act</td>
<td>Data regarding the usage, or the potential benefits or risks, of a drug derived from sources other than randomized clinical trials.</td>
</tr>
<tr>
<td>International Society of Pharmacoeconomics and Outcomes Research of RWD (ISPOR) (ISPOR Real- World Data Task Force, 2016)</td>
<td>Data used for clinical, coverage, and payment decision-making that are not collected in conventional randomized controlled trials (RCTs). Real-world data could be characterized in a number of different ways, e.g., by type of outcome, by location in a hierarchy of evidence, or by type of data source.</td>
</tr>
</tbody>
</table>
| FDA- Center for Evaluation Research (CDER) “Working Definitions” of RWD and RWE (FDA, 2017) | **Real-World Data (RWD):** Data relating to patient health status and/or the delivery of health care routinely collected from a variety of sources.  
**Real-World Evidence (RWE):** The clinical evidence regarding the usage and potential benefits or risks of a medical product derived from analysis of RWD.  
**Examples of RWD include:** Data derived from electronic health records (EHRs), claims and billing data, data from product and disease registries, patient-generated data including in home-use settings, and data gathered from other sources that can inform on health status, such as mobile devices.  
**Sources of RWD include:** Registries, collections of EHRs, and administrative and health care claims databases, among others. RWD sources such as these can be used as data collection and analysis infrastructure to support many types of trial designs, including, but not limited to, randomized trials, such as large simple trials, pragmatic clinical trials, and observational studies (prospective and/or retrospective). |
RANDOMIZED CONTROLLED TRIALS (RCT)

RANDOMIZED CONTROLLED TRIALS (RCT) CONTINUE TO BE THE GOLD STANDARD FOR ASSESSING EFFICACY OF NEW DRUGS BUT THEY HAVE LIMITATIONS IN PROVIDING INFORMATION FOR HTA:

- May not reflect how effective a drug would be in real clinical practice
- Patients are preselected, short time frames, limited sample size, driven by trial protocol
- This creates concern about the validity of economic models driven by RCT outcomes e.g. For cancers of rare genetic sub-types RCT evidence alone may not provide sufficient data on patient survival and outcomes. (Phase II data only)

Emerging sources of data captured in “real world” treatment settings & patient populations offer opportunities for a deeper understanding of why and for whom treatments work (or not) to help fill the gaps from RCTs.
pCODR – UNCERTAINTY AROUND CLINICAL OUTCOMES

THE MAJORITY OF pCODR RECOMMENDATIONS FOR ONCOLOGY DRUGS ARE CONDITIONAL UPON IMPROVEMENT IN COST EFFECTIVENESS AND/OR CONFIRMATION OF CLINICAL EFFICACY.

• Conditional recommendations stem from uncertainty around clinical outcomes, safety parameters and quality of life which impacts the validity of economic models.

• Clinical uncertainty is a result of data submitted for HTA, which is typically based on structured Phase III trials over time frames that may not be relevant to treatment in real clinical practice.
THIS UNCERTAINTY COULD BE ADDRESSED WITH ADDITIONAL PROSPECTIVE OR RWE DATA COLLECTION.

• A study of 60 pCODR recommendations up to February 2016 showed that in 21 reviews there were 23 requests.

• 13 pCODR reviews explicitly requested RWE, 10 pCODR reviews potentially requested RWE.
RWE REQUESTED IN pCODR DECISIONS:

✓ Prospective evidence to help determine magnitude of clinical benefit.

✓ Information on efficacy, QoL and strategies for long term control in patients.

✓ Data on treatment duration, patient monitoring to better define drug tapering and stopping criteria.

✓ Information on efficacy and safety in patient sub-populations.
CADTH recognized the potential limitations of clinical trial data in some situations

“In certain exceptional cases, there may be practical challenges in conducting robust clinical trials and pharmacoeconomic evaluations. Under these conditions there may be a recommendation for listing with Real World Evidence development for scenarios where there is uncertain clinical benefit, but significant unmet need.”

CADTH, March 2016

PROVINCIAL Payers, operating with constrained budgets also have concerns about the clinical and cost effectiveness of new oncology drugs and have also stated the need for RWE to support drug reimbursement decision making.

e.g. Cancer Care Ontario (CCO), the Ministry of Health and Long-Term Care (MOHLTC), the Canadian Association of Provincial Cancer Agencies (CAPCA) have recommended that RWE should be used to inform and monitor the effects of funding decisions.
**THE PAN-CANADIAN ONCOLOGY DRUG REVIEW (pCODR)**

- pCODR assesses new oncology products and makes funding recommendations to the provinces/territories (except Quebec) for cancer drugs for reimbursement

**PATIENT/PATIENT GROUP INPUT IS REVIEWED BY THE pCODR EXPERT REVIEW COMMITTEE**
INESSS invites citizens, patients, caregivers and health professionals, as well as their associations and groups, to provide information on issues from the participants' specific knowledge or experiences on a particular drug.

- **Reasonableness of the Price**
- **Cost Effectiveness of the Medication**
- **Therapeutic Value**

- Advisability of adding the medication to the list with regard to the purpose of the basic prescription drug insurance plan
- The impact of adding the medication to the list will have on the health of the population and on the other components of the health care system
<table>
<thead>
<tr>
<th>pCODR</th>
<th>Sub-Criteria</th>
<th>Sub-Criteria Definitions</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Overall Clinical Benefit</strong></td>
<td>Effectiveness (systematic review in the Clinical Guidance Report)</td>
<td>The potential health impact of the drug compared to the other drug and non-drug alternatives, measured in terms of relevant patient outcomes such as mortality, morbidity, quality of life. Magnitude, direction and uncertainty of effect should be considered.</td>
</tr>
<tr>
<td></td>
<td>Safety (systematic review in the Clinical Guidance Report)</td>
<td>Frequency and severity of adverse effects associate with the new drug compared to other drug and non-drug alternatives.</td>
</tr>
<tr>
<td></td>
<td>Burden of Illness (Clinical Guidance Report, PAG)</td>
<td>Incidence, prevalence or other measure of disease burden on the population.</td>
</tr>
<tr>
<td></td>
<td>Need (Clinical Guidance Report, PAG)</td>
<td>Availability of an effective alternative to the drug technology.</td>
</tr>
<tr>
<td><strong>Alignment with Patient Values</strong></td>
<td>Patient Values (Patient Advocacy Group Input)</td>
<td>Patient based values which bear on the appropriate use and impact of the drug.</td>
</tr>
<tr>
<td><strong>Cost Effectiveness</strong></td>
<td>Economic Evaluations (Economic Guidance Report and pharmacoeconomic model review)</td>
<td>A measure of the net cost or efficiency of the drug and companion technology compared to other drug and non-drug alternatives. The uncertainty of results should be considered.</td>
</tr>
<tr>
<td><strong>Feasibility of Adoption into Health Systems</strong></td>
<td>Economic Feasibility (evaluation of budget impact assessment in Economic Guidance Report)</td>
<td>The net budget impact of the new drug on other drug and health system spending, including companion testing technology.</td>
</tr>
<tr>
<td></td>
<td>Organizational Feasibility</td>
<td>The economic feasibility of economic impact on the health system and health care technology.</td>
</tr>
</tbody>
</table>
PATIENT EVIDENCE

Experiential Evidence in respect of:

Living with Illness

Nature of Illness

Needs & Expectations of Treatment

Limitations that illness/Tx imposes on Pt, family or caregiver
Patient Group Engagement In Canadian Clinical Trials System

**Preclinical**
- Fundraising and direct funding for research
- Provide biosamples
- Help define study’s eligibility criteria
- Patient registry support
- Input on meaningful clinical endpoints/patient-reported outcomes (PROs)
- Ensure capture of post-trial information through Real World Evidence
- Assist with informed consent form/process
- Work with Health Canada on benefit-risk and draft guidance
- Accompany sponsor to pre-IND Health Canada meeting to advocate for study

**Phase I/II/III clinical trials**
- Engage with Health Canada to provide patient perspective
- Fundraising and direct funding for research
- Provide biosamples
- Help define study’s eligibility criteria
- Patient registry support
- Input on meaningful clinical endpoints/patient-reported outcomes (PROs)
- Ensure capture of post-trial information through Real World Evidence
- Assist with informed consent form/process
- Work with Health Canada on benefit-risk and draft guidance
- Accompany sponsor to pre-IND Health Canada meeting to advocate for study

**Post approval studies & outcomes**
- Serve on postmarket surveillance initiatives
- Help return study results to participants
- Co-present results
- Publications/communications, etc.
- Feedback on how patient community views results
- Patient registry support
- Provide patient group input into Health Technology Assessments (e.g., pCODR/}

*Adapted from the Clinical Trials Transformation Initiative (CTTI)*
RWE STUDIES CAN PROVIDE:

- Effectiveness and safety data for patient populations over disease-relevant timeframes;
- Adherence to treatment and dose changes over time;
- Time to discontinuation of therapy and medication switching patterns;
- Cost of therapy to support ongoing drug cost-effectiveness estimations;
- Time to a defined response;
- Physician prescribing patterns and identification of potential limitations of current treatment guidelines;
- Patient concomitant medication utilization and changes over time;
- Patient reported outcomes (satisfaction with therapy; quality of life; utility; out-of-pocket disease expenses; caregiver burden) which can be used to support cost-effectiveness estimations and
- Expanded reimbursement;
- Burden of disease (e.g., particularly for rare cancers) which can support requests for wider reimbursement.
PREVENTABLE,
TREATABLE,
BEATABLE!

Barry D. Stein
barrys@colorectalcancercanada.com
colorectalcancercanada.com
Patient Perspectives on Real World Evidence & Real World Data

Taking Action on Real World Evidence: From Analysis to Impact

Session 2: Stakeholder Engagement in RWE Oncology
October 22, 2018

Barry D. Stein
President CSO
Patients want …

✓ RWE generated from their experiences to be incorporated into value-driven decision making and policy discussions to ensure that the outcomes most important to them are considered.

✓ **More control of their data** and how it is used; they want their data used for research, but, generally do not want it used for only commercial purposes.

✓ **Patients need** a better understanding of RWE to both use and contribute.

Policymakers and advisory groups need to invest in educational efforts to inform and fully include the patient community in initiatives to establish standards for RWD and to use RWE more effectively.
Stakeholder Engagement in Real World Evidence in Oncology

CAPT 2018 Conference

October 22, 2018
10:45 a.m. – 12:00 noon
VIRGINIE GIROUX

Director, HEOR and Real World Evidence
Merck Canada
Real World Data

- Different outcomes versus clinical trial setting
- Insights into day-to-day care of patients
- Various sources (EMR, claims, pharmacies, hospital, wearables, etc.)
Value Beyond Clinical Trial Measures

Patient perspectives

Real world performance

Other outcomes

Benefits of precision medicine
Patient-Centric & Collaborative Approach

A Strong and Collaborative Working Relationship with Patients, Payers, the Regulator and Health Care Community
Optimal Approach

• Need to work together to develop RWE approach
• Collaborative pilot projects to:
  – Help define roles of stakeholders (i.e., HTA, payers, industry, patients and clinicians)
  – Gain insights into, and find ways to address, practical challenges (e.g., data quality, sources, methods, access to data, etc.)
  – Gain better understanding of how to use RWE to demonstrate effectiveness and safety
• Scale up once approach has been fine-tuned
• Ensure flexibility to continue to adjust approach as needed
Merck-Regenstrief Collaboration

• Partnership with the Regenstrief Institute, Indiana University
• Started multi-year collaboration in 2012 and recently renewed
• Seeks to understand how to use real-world data to better understand effectiveness of therapies

"Both parties bring something different to the table... We bring different perspectives and viewpoints but one unified goal: to get patients access to care in an affordable, effective, and efficient way."

—Susan Shiff, Ph.D., senior vice president of Merck’s Center for Observational and Real-World Evidence (CORE)

CORE is the arm of Merck that harnesses real-world and observational data to provide the best available information on the value of our medicines and the products that we bring to the market.
Merck-Regenstrief Collaboration (Continued…)

- Multiple scientists have worked on many projects to produce useful materials and insights

- Both Merck and the Regenstrief Institute see the collaboration as a different way of looking at the patient's interaction with the healthcare system
QUESTIONS & DISCUSSION